The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.
18-Feb-2014 - Actavis has confirmed it will acquire Forest Laboratories in a deal worth up to $25bn (€18bn) following rumours last night.
06-Feb-2014 - An increased trend in dealmaking for targeted drug delivery last year will continue to drive partnerships in 2014, according to a pharmaceutical partnering expert.
03-Feb-2014 - Lupin Ltd has bought Dutch delivery technology company Nanomi BV in a deal that moves the Indian generics firm into the complex injectables space.
23-Jan-2014 - Increased in-house API production and manufacturing in India will lower the costs of Hospira’s injectables, the firm says, as it looks past current remediation efforts.
16-Jan-2014 - Complex generics will represent over 50% of Teva’s generic market by 2017, the firm says, but investments in delivery technology will have positive implications across the full business.
13-Jan-2014 - Alnylam has both acquired Merck & Co. subsidiary Sirna therapeutics and extended an alliance with Genzyme in order to advance its small interfering RNA (siRNA) delivery programme.
07-Jan-2014 - Aerogen has licensed its respiratory drug delivery technology to Dutch electronics giant Philips in a deal announced today.
06-Jan-2014 - Chinese API firm Shenzhen Hepalink has announced plans to buy Scientific Protein Laboratories (SPL) from private equity investor American Capital for $337.5m.
18-Dec-2013 - Encap has collaborated with Lipocine to manufacture its oral testosterone product and says it expects continued growth in demand for HPAPI formulation services.
25-Nov-2013 - Pfizer says it intends to shutter a manufacturing facility in Puerto Rico just days after Merck & Co. announced it was reducing its footprint on the island.
21-Nov-2013 - Aptar Pharma has launched a new auto-injector technology as part of a strategic effort to build its presence in the biopharmaceutical sector.
04-Nov-2013 - Granules India has outlined plans to buy drug intermediate and API maker Auctus Pharma, set up an actives R&D site and announced its intention to wind up its ‘shell’ operation...
31-Oct-2013 - The acquisition of Bend Research by Capsugel may be “a marriage made in heaven” for customers, the firms say, as the first drug delivery tech is transferred.
23-Oct-2013 - Catalent has announced two new softgel solutions as it adds greater versatility to its Advanced Technologies Business Unit.
15-Oct-2013 - AstraZeneca has become the latest company to invest in antibody-drug conjugate (ADC) technology with the acquisition of Spirogen for $200m (€148m).
09-Oct-2013 - Merck says it is shutting two New Jersey facilities as it moves its headquarters to the Kenilworth site where manufacturing ended last week.
05-Sep-2013 - Capsugel will buy Bend Research to expand its dosage form solutions (DFS) business in a deal announced earlier today.
05-Sep-2013 - GlaxoSmithKline is in talks with a number of companies interested in buying its Romanian manufacturing facility that was recently earmarked for closure.
02-Sep-2013 - Novartis-owned Chiron and Panacea Biotec have amicably dissolved their vaccine joint venture due to strategic regions, according to Novartis.
29-Aug-2013 - ICIG will buy the Belgian operation of peptide maker Peptisyntha SA from Solvay to expand its recently rejigged contract API business.
28-Aug-2013 - Amgen spent $10.4bn (€7.8bn) this week on Onyx Pharmaceuticals, but AstraZeneca and Johnson & Johnson have also opened up their wallets this week – welcome to in-Pharmatechnologist.com’s merger & acquisition...
26-Aug-2013 - Amgen has spent $10.4bn (€7.8bn) in acquiring Onyx Pharmaceuticals saying its oncology products and pipeline will be strengthened by Amgen’s manufacturing capabilities.
20-Aug-2013 - Fresenius Kabi will focus on intravenous generics and infusion solutions as it acquires a 51 percent stake in an Indonesian pharma company.
14-Aug-2013 - Pharmstandard says the acquisition of Bever Pharmaceuticals will lower the cost of its API supply as it plans to spin out an OTC business.
13-Aug-2013 - Consolidating its Indian injectable business under a new subsidiary will improve focus and align quality control, says Aurobindo who has invested in two manufacturing companies to support such plans.